Tenecteplase

證據等級: L5

預測適應症: 10 個

Tenecteplase: From Undocumented Original Indication to Posterolateral Myocardial Infarction

One-Sentence Summary

Tenecteplase (DB00031) is a recombinant tissue plasminogen activator (TNK-tPA); its originally approved indication is not documented in this evidence pack, and it currently holds no marketing authorisation in Denmark. The TxGNN model’s top-ranked prediction is posterolateral myocardial infarction, with a 99.87% prediction score, but this specific candidate is supported by zero clinical trials and zero literature in the evidence pack — it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not documented — `taiwan_regulatory.licenses` is empty (no Danish MA on file) and `original_indications` was not populated in this pack
Predicted New Indication	Posterolateral Myocardial Infarction
TxGNN Prediction Score	99.87%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the drug’s known pharmacological class, tenecteplase is a genetically engineered variant of tissue plasminogen activator (TNK-tPA) that catalyzes the conversion of plasminogen to plasmin, dissolving fibrin clots.

Posterolateral myocardial infarction is an anatomical-location subtype of myocardial infarction, a condition for which thrombolytic agents in this class are mechanistically relevant. The evidence pack’s own rationale for this candidate states: this subtype “is theoretically consistent with tenecteplase’s standard thrombolytic mechanism, but no trial or literature in this dataset directly supports it — only the TxGNN score exists — and it substantially overlaps with myocardial infarction as a general condition, raising the possibility that this is an ontology-level duplicate rather than a genuinely novel indication.”

In other words, the mechanistic plausibility is high, but that plausibility likely reflects tenecteplase’s already-established relevance to myocardial infarction generally, rather than new evidence specific to the posterolateral subtype. This is why the evidence pack itself scores this candidate L5 and recommends Hold.

Note for context: within the same evidence pack, a different candidate — coronary stenosis (rank 9/10) — has materially stronger support, including a completed Phase 2 RCT (NCT00604695, low-dose intracoronary tenecteplase during primary PCI) and 12 literature hits, reaching evidence level L2 with a “Proceed with Guardrails” recommendation. That candidate may warrant separate evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Tenecteplase currently holds no marketing authorisation in Denmark — total_licenses is 0 and no license records are on file in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (Key warnings, contraindications, and drug-interaction data are all marked as data gaps in this evidence pack; the DDI query itself returned “not found.”)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has no direct clinical-trial or literature support in the evidence pack — only a TxGNN model score — and the predicted indication is anatomically nested within myocardial infarction, a condition already closely tied to tenecteplase’s known thrombolytic mechanism. This raises meaningful risk that the “new indication” is an ontology artifact rather than a genuine repurposing opportunity, so it does not meet the bar to proceed.

To proceed, the following is needed:

Original indication and mechanism-of-action data (DG002 remediation, via DrugBank API), to establish whether this candidate is truly distinct from tenecteplase’s existing use
TFDA/SmPC label, warnings, and contraindications (DG001 remediation, currently Blocking) before any S1 safety review can begin
Targeted literature/trial search specific to “posterolateral myocardial infarction” (as opposed to myocardial infarction generally) to determine if this subtype has been studied independently
If pursuing repurposing work on this drug, consider prioritizing the coronary stenosis candidate instead, which already has L2-level evidence including a completed Phase 2 RCT
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.